Changes in HIV-1 Subtypes/Sub-Subtypes,and Transmitted Drug Resistance Among ART-Naïve HIV-Infected Individuals—China,2004–2022
作者机构：State Key Laboratory of Infectious Disease Prevention and Control(SKLID)National Center for AIDS/STD Control and PreventionChinese Center for Disease Control and Prevention(China CDC)Collaborative Innovation Center for Diagnosis and Treatment of Infectious DiseasesBeijingChina.
出 版 物：《China CDC weekly》 (中国疾病预防控制中心周报（英文）)
年 卷 期：2023年第5卷第30期
页 面：664-671,I0010-I0012页
核心收录：
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
基 金：Supported by the Ministry of Science and Technology of China(grant numbers 2022YFC2305205,2022YFC2305201) the National Natural Science Foundation of China(grant number 82260670) Guangxi Bagui Honor Scholarship and Chinese State Key Laboratory of Infectious Disease Prevention and Control
主 题：prevalence alterations drugs
摘 要：Introduction:The efficacy of treatment and clinical outcomes may be jeopardized by factors such as transmitted drug resistance(TDR)and the genetic diversity of the human immunodeficiency virus type 1(HIV-1).This comprehensive study aims to examine the alterations in HIV-1 subtypes or sub-subtypes and TDR among Chinese individuals,who have been diagnosed with HIV infection and are previously untreated with antiretroviral therapy(ART),across the span of 2004 to ***:Sequences of the HIV-1 pol gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and *** predict susceptibility to 12 antiretroviral drugs,the research utilized the Stanford HIV Drug Resistance *** Cochran-Armitage trend test facilitated the analysis of changes in HIV-1 subtype/sub-subtype prevalence and *** analysis was conducted in alignment with the progression of the National Free Antiretroviral Treatment Program’s stages between 2004 and ***:Among the 57,902 ART-naïve individuals infected with HIV,there was a notable decline in the prevalence of CRF01_AE,B,and C from 37.3%,24.1%,and 1.3%respectively in 2004–2007 to 29.4%,7.3%,and 0.2%respectively in 2020–***,a significant increase was observed in the proportions of CRF07_BC,CRF08_BC,CRF55_01B,other CRFs,and URFs,from 24.1%,11.5%,0.1%,0.4%,and 0.9%respectively in 2004–2007 to 40.8%,11.5%,3.8%,3.7%,and 2.8%respectively in 2020–2022(all P0.001 for trend).The prevalence of TDR to overall,non-nucleoside reverse transcriptase inhibitor(NNRTI),efavirenz,and nevirapine also significantly increased from 2.6%,1.8%,1.6%,and 1.8%respectively in 2004–2007 to 7.8%,6.7%,6.3%,and 6.7%respectively in 2020–2022(all P0.001 for trend).However,there were no meaningful changes in the TDR prevalence of nucleoside reverse transcriptase inhibitor and protease ***,in 2020–2022,the overall TDR prevalence exceeded 15%in ***
维普期刊数据库